The Fort Worth-based Rainwater Charitable Foundation awarded more than $1 million through its inaugural Sprint to Lead program to support three researchers developing experimental treatments for tau-related neurodegenerative diseases. Each researcher received $350,000 to advance a different approach: reducing excess tau protein, developing compounds that break down harmful tau, or preventing tau from forming disease-associated structures. The one-year projects aim to move promising drug candidates closer to further preclinical testing and potential future treatments for conditions such as progressive supranuclear palsy, corticobasal degeneration, and frontotemporal degeneration.
